Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2000 Jun 1;348(Pt 2):359–365.

Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides.

T Tokuda 1, M Calero 1, E Matsubara 1, R Vidal 1, A Kumar 1, B Permanne 1, B Zlokovic 1, J D Smith 1, M J Ladu 1, A Rostagno 1, B Frangione 1, J Ghiso 1
PMCID: PMC1221074  PMID: 10816430

Abstract

The inheritance of the apolipoprotein E (apoE) epsilon4 allele is a prevailing risk factor for sporadic and familial Alzheimer's disease (AD). ApoE isoforms bind directly to Alzheimer's amyloid beta (Abeta) peptides both in vitro and in vivo. Recent studies suggest that association of apoE with lipids may modulate its interaction with Abeta. We examined the binding of lipid-associated and delipidated apoE3 and apoE4 isoforms to Abeta utilizing a solid-phase binding assay and estimated the dissociation constants for the interaction of various apoE and Abeta species. Using native apoE isoforms from stably transfected RAW 264 and human embryonic kidney 293 cells, apoE3 had greater affinity than apoE4 for both Abeta1-40 and Abeta1-42. Delipidation of apoE decreased its affinity for Abeta peptides by 5-10-fold and abolished the isoform-specificity. Conversely, incorporation of apoE isoforms produced by baculovirus-infected Sf9 cells into reconstituted human high-density-lipoprotein lipoparticles restored the affinity values for Abeta peptides and resulted in preferential binding of apoE3. The data demonstrate that native lipid-associated apoE3 binds to Abeta peptides with 2-3-fold higher affinity than lipid-associated apoE4. Since the isoforms' binding efficiency correlate inversely with the risk of developing late-onset AD, the results suggest a possible involvement of apoE3 in the clearance or routing out of Abeta from the central nervous system as one of the mechanisms underlying the pathology of the disease.

Full Text

The Full Text of this article is available as a PDF (167.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aleshkov S. B., Li X., Lavrentiadou S. N., Zannis V. I. Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide beta (1-40). Biochemistry. 1999 Jul 13;38(28):8918–8925. doi: 10.1021/bi982002q. [DOI] [PubMed] [Google Scholar]
  2. Aleshkov S., Abraham C. R., Zannis V. I. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Biochemistry. 1997 Aug 26;36(34):10571–10580. doi: 10.1021/bi9626362. [DOI] [PubMed] [Google Scholar]
  3. Bales K. R., Verina T., Dodel R. C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E. M., Little S. P., Cummins D. J. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997 Nov;17(3):263–264. doi: 10.1038/ng1197-263. [DOI] [PubMed] [Google Scholar]
  4. Calero M., Tokuda T., Rostagno A., Kumar A., Zlokovic B., Frangione B., Ghiso J. Functional and structural properties of lipid-associated apolipoprotein J (clusterin). Biochem J. 1999 Dec 1;344(Pt 2):375–383. [PMC free article] [PubMed] [Google Scholar]
  5. Chacko G. K., Mahlberg F. H., Johnson W. J. Cross-linking of apoproteins in high density lipoprotein by dimethylsuberimidate inhibits specific lipoprotein binding to membranes. J Lipid Res. 1988 Mar;29(3):319–324. [PubMed] [Google Scholar]
  6. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993 Aug 13;261(5123):921–923. doi: 10.1126/science.8346443. [DOI] [PubMed] [Google Scholar]
  7. Forte T. M., Nordhausen R. W. Electron microscopy of negatively stained lipoproteins. Methods Enzymol. 1986;128:442–457. doi: 10.1016/0076-6879(86)28086-6. [DOI] [PubMed] [Google Scholar]
  8. Ghiso J., Calero M., Matsubara E., Governale S., Chuba J., Beavis R., Wisniewski T., Frangione B. Alzheimer's soluble amyloid beta is a normal component of human urine. FEBS Lett. 1997 May 12;408(1):105–108. doi: 10.1016/s0014-5793(97)00400-6. [DOI] [PubMed] [Google Scholar]
  9. Holtzman D. M., Bales K. R., Wu S., Bhat P., Parsadanian M., Fagan A. M., Chang L. K., Sun Y., Paul S. M. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest. 1999 Mar;103(6):R15–R21. doi: 10.1172/JCI6179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Innerarity T. L., Pitas R. E., Mahley R. W. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J Biol Chem. 1979 May 25;254(10):4186–4190. [PubMed] [Google Scholar]
  11. Koudinov A., Matsubara E., Frangione B., Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1164–1171. doi: 10.1006/bbrc.1994.2788. [DOI] [PubMed] [Google Scholar]
  12. LaDu M. J., Falduto M. T., Manelli A. M., Reardon C. A., Getz G. S., Frail D. E. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994 Sep 23;269(38):23403–23406. [PubMed] [Google Scholar]
  13. LaDu M. J., Gilligan S. M., Lukens J. R., Cabana V. G., Reardon C. A., Van Eldik L. J., Holtzman D. M. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem. 1998 May;70(5):2070–2081. doi: 10.1046/j.1471-4159.1998.70052070.x. [DOI] [PubMed] [Google Scholar]
  14. LaDu M. J., Lukens J. R., Reardon C. A., Getz G. S. Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. J Neurosci Res. 1997 Jul 1;49(1):9–18. [PubMed] [Google Scholar]
  15. LaDu M. J., Pederson T. M., Frail D. E., Reardon C. A., Getz G. S., Falduto M. T. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J Biol Chem. 1995 Apr 21;270(16):9039–9042. doi: 10.1074/jbc.270.16.9039. [DOI] [PubMed] [Google Scholar]
  16. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., Morgan T. E., Rozovsky I., Trommer B., Viola K. L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448–6453. doi: 10.1073/pnas.95.11.6448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Matsubara E., Frangione B., Ghiso J. Characterization of apolipoprotein J-Alzheimer's A beta interaction. J Biol Chem. 1995 Mar 31;270(13):7563–7567. doi: 10.1074/jbc.270.13.7563. [DOI] [PubMed] [Google Scholar]
  18. Matz C. E., Jonas A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem. 1982 Apr 25;257(8):4535–4540. [PubMed] [Google Scholar]
  19. Miyata M., Smith J. D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996 Sep;14(1):55–61. doi: 10.1038/ng0996-55. [DOI] [PubMed] [Google Scholar]
  20. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991 Feb 8;541(1):163–166. doi: 10.1016/0006-8993(91)91092-f. [DOI] [PubMed] [Google Scholar]
  21. Nathan B. P., Bellosta S., Sanan D. A., Weisgraber K. H., Mahley R. W., Pitas R. E. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994 May 6;264(5160):850–852. doi: 10.1126/science.8171342. [DOI] [PubMed] [Google Scholar]
  22. Näslund J., Schierhorn A., Hellman U., Lannfelt L., Roses A. D., Tjernberg L. O., Silberring J., Gandy S. E., Winblad B., Greengard P. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8378–8382. doi: 10.1073/pnas.91.18.8378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Näslund J., Thyberg J., Tjernberg L. O., Wernstedt C., Karlström A. R., Bogdanovic N., Gandy S. E., Lannfelt L., Terenius L., Nordstedt C. Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron. 1995 Jul;15(1):219–228. doi: 10.1016/0896-6273(95)90079-9. [DOI] [PubMed] [Google Scholar]
  24. Oda T., Wals P., Osterburg H. H., Johnson S. A., Pasinetti G. M., Morgan T. E., Rozovsky I., Stine W. B., Snyder S. W., Holzman T. F. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol. 1995 Nov;136(1):22–31. doi: 10.1006/exnr.1995.1080. [DOI] [PubMed] [Google Scholar]
  25. Osborne J. C., Jr Delipidation of plasma lipoproteins. Methods Enzymol. 1986;128:213–222. doi: 10.1016/0076-6879(86)28069-6. [DOI] [PubMed] [Google Scholar]
  26. Pitas R. E., Boyles J. K., Lee S. H., Foss D., Mahley R. W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987 Jan 13;917(1):148–161. doi: 10.1016/0005-2760(87)90295-5. [DOI] [PubMed] [Google Scholar]
  27. Poirier J., Hess M., May P. C., Finch C. E. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res Mol Brain Res. 1991 Sep;11(2):97–106. doi: 10.1016/0169-328x(91)90111-a. [DOI] [PubMed] [Google Scholar]
  28. Rebeck G. W., Reiter J. S., Strickland D. K., Hyman B. T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993 Oct;11(4):575–580. doi: 10.1016/0896-6273(93)90070-8. [DOI] [PubMed] [Google Scholar]
  29. Saunders A. M., Strittmatter W. J., Schmechel D., George-Hyslop P. H., Pericak-Vance M. A., Joo S. H., Rosi B. L., Gusella J. F., Crapper-MacLachlan D. R., Alberts M. J. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993 Aug;43(8):1467–1472. doi: 10.1212/wnl.43.8.1467. [DOI] [PubMed] [Google Scholar]
  30. Schmechel D. E., Saunders A. M., Strittmatter W. J., Crain B. J., Hulette C. M., Joo S. H., Pericak-Vance M. A., Goldgaber D., Roses A. D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9649–9653. doi: 10.1073/pnas.90.20.9649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992 Sep 24;359(6393):325–327. doi: 10.1038/359325a0. [DOI] [PubMed] [Google Scholar]
  32. Shoji M., Golde T. E., Ghiso J., Cheung T. T., Estus S., Shaffer L. M., Cai X. D., McKay D. M., Tintner R., Frangione B. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 1992 Oct 2;258(5079):126–129. doi: 10.1126/science.1439760. [DOI] [PubMed] [Google Scholar]
  33. Smith J. D., Melián A., Leff T., Breslow J. L. Expression of the human apolipoprotein E gene is regulated by multiple positive and negative elements. J Biol Chem. 1988 Jun 15;263(17):8300–8308. [PubMed] [Google Scholar]
  34. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., Roses A. D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977–1981. doi: 10.1073/pnas.90.5.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L. M., Salvesen G. S., Pericak-Vance M., Schmechel D., Saunders A. M., Goldgaber D., Roses A. D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8098–8102. doi: 10.1073/pnas.90.17.8098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tabaton M., Nunzi M. G., Xue R., Usiak M., Autilio-Gambetti L., Gambetti P. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994 May 16;200(3):1598–1603. doi: 10.1006/bbrc.1994.1634. [DOI] [PubMed] [Google Scholar]
  37. Teller J. K., Russo C., DeBusk L. M., Angelini G., Zaccheo D., Dagna-Bricarelli F., Scartezzini P., Bertolini S., Mann D. M., Tabaton M. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med. 1996 Jan;2(1):93–95. doi: 10.1038/nm0196-93. [DOI] [PubMed] [Google Scholar]
  38. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., Schenk D. B. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993 Nov;61(5):1965–1968. doi: 10.1111/j.1471-4159.1993.tb09841.x. [DOI] [PubMed] [Google Scholar]
  39. Wisniewski T., Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992 Feb 3;135(2):235–238. doi: 10.1016/0304-3940(92)90444-c. [DOI] [PubMed] [Google Scholar]
  40. Wisniewski T., Ghiso J., Frangione B. Biology of A beta amyloid in Alzheimer's disease. Neurobiol Dis. 1997;4(5):313–328. doi: 10.1006/nbdi.1997.0147. [DOI] [PubMed] [Google Scholar]
  41. Wisniewski T., Golabek A., Matsubara E., Ghiso J., Frangione B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun. 1993 Apr 30;192(2):359–365. doi: 10.1006/bbrc.1993.1423. [DOI] [PubMed] [Google Scholar]
  42. Wisniewski T., Lalowski M., Golabek A., Vogel T., Frangione B. Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet. 1995 Apr 15;345(8955):956–958. doi: 10.1016/s0140-6736(95)90701-7. [DOI] [PubMed] [Google Scholar]
  43. Wujek J. R., Dority M. D., Frederickson R. C., Brunden K. R. Deposits of A beta fibrils are not toxic to cortical and hippocampal neurons in vitro. Neurobiol Aging. 1996 Jan-Feb;17(1):107–113. doi: 10.1016/0197-4580(95)02020-9. [DOI] [PubMed] [Google Scholar]
  44. Yokoyama S., Kawai Y., Tajima S., Yamamoto A. Behavior of human apolipoprotein E in aqueous solutions and at interfaces. J Biol Chem. 1985 Dec 25;260(30):16375–16382. [PubMed] [Google Scholar]
  45. Yokoyama S. Self-associated tetramer of human apolipoprotein E does not lead to its accumulation on a lipid particle. Biochim Biophys Acta. 1990 Oct 22;1047(1):99–101. doi: 10.1016/0005-2760(90)90266-z. [DOI] [PubMed] [Google Scholar]
  46. Zannis V. I., Breslow J. L. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry. 1981 Feb 17;20(4):1033–1041. doi: 10.1021/bi00507a059. [DOI] [PubMed] [Google Scholar]
  47. Zhou Z., Smith J. D., Greengard P., Gandy S. Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Mol Med. 1996 Mar;2(2):175–180. [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES